The 2022 World Health Organization classification of tumors of the urinary system and male genital organs—part B: prostate and urinary tract tumors
Abstract The 2022 World Health Organization (WHO) classification of the urinary and male
genital tumors was recently published by the International Agency for Research on Cancer …
genital tumors was recently published by the International Agency for Research on Cancer …
Current best practice for bladder cancer: a narrative review of diagnostics and treatments
E Compérat, MB Amin, R Cathomas, A Choudhury… - The Lancet, 2022 - thelancet.com
This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …
European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update
M Babjuk, M Burger, EM Compérat, P Gontero… - European urology, 2019 - Elsevier
Context This overview presents the updated European Association of Urology (EAU)
guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ …
guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ …
The 2016 WHO classification of tumours of the urinary system and male genital organs—part B: prostate and bladder tumours
PA Humphrey, H Moch, AL Cubilla, TM Ulbright… - European urology, 2016 - Elsevier
It has been 12 yr since the publication of the last World Health Organization (WHO)
classification of tumours of the prostate and bladder. During this time, significant new …
classification of tumours of the prostate and bladder. During this time, significant new …
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
LJ Esserman, IM Thompson, B Reid, P Nelson… - The lancet …, 2014 - thelancet.com
A vast range of disorders—from indolent to fast-growing lesions—are labelled as cancer.
Therefore, we believe that several changes should be made to the approach to cancer …
Therefore, we believe that several changes should be made to the approach to cancer …
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
J Bellmunt, A Orsola, JJ Leow, T Wiegel… - Annals of …, 2014 - annalsofoncology.org
In Europe, an estimated 151 297 new cases of bladder cancer were diagnosed in 2012, with
an age-standardised incidence rate (per 100000 persons) of 17.7 for males and 3.5 for …
an age-standardised incidence rate (per 100000 persons) of 17.7 for males and 3.5 for …
Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non–muscle-invasive bladder …
V Soukup, O Čapoun, D Cohen, V Hernandez… - European urology, 2017 - Elsevier
Context Tumour grade is an important prognostic indicator in non–muscle-invasive bladder
cancer (NMIBC). Histopathological classifications are limited by interobserver variability …
cancer (NMIBC). Histopathological classifications are limited by interobserver variability …
Overdiagnosis and overtreatment in cancer: an opportunity for improvement
LJ Esserman, IM Thompson, B Reid - Jama, 2013 - jamanetwork.com
Over the past 30years, awareness and screening have led to an emphasis on early
diagnosis of cancer. Although the goals of these efforts were to reduce the rate oflate …
diagnosis of cancer. Although the goals of these efforts were to reduce the rate oflate …
Bladder cancer
Bladder cancer is a complex disease associated with high morbidity and mortality rates if not
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …
Bladder cancer
DS Kaufman, WU Shipley, AS Feldman - The Lancet, 2009 - thelancet.com
Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial
tumours, which tend to recur but are generally not life threatening, and 30% presenting as …
tumours, which tend to recur but are generally not life threatening, and 30% presenting as …